What is AIM ImmunoTech's market cap?

AIM ImmunoTech (AIM) has a market capitalization of $8.0M and trades on AMEX.

Who are AIM ImmunoTech's competitors?

AIM ImmunoTech's key competitors include Pfizer, Novartis, Revolution Medicines, and others. These companies compete in similar markets and product categories.

Who does AIM ImmunoTech partner with?

AIM ImmunoTech's notable partners include AstraZeneca, Thermo Fisher Scientific, Merck & Co., and others.

What subsidiaries does AIM ImmunoTech have?

AIM ImmunoTech's subsidiaries include AIM ImmunoTech Europe N.V./S.A..

Where is AIM ImmunoTech headquartered?

AIM ImmunoTech is headquartered in United States of America and employs approximately 28 people. It has been publicly traded since 1995.

AIM ImmunoTech

AIM

AIM ImmunoTech is an immuno-pharmaceutical company focused on the research and development of therapeutics for cancers, viral diseases, and immune-deficiency disorders.

Market cap

$8.04M+12.4%

Table of contents

Earnings

Q1 2026 report

May 15, 2026

Revenue$22.0KBeat by $11.0K EPS-$0.69Beat by $0.39

Read the full report

Next report

Aug 13, 2026 (in a month)

Revenue estimate$100.0K

EPS estimate-$0.17

Competitors

By market cap

Pfizer$138.21B-3.7%

Revolution Medicines, Inc.$40.6B+495%

Baxter International$11.6B-23.9%

ImmunityBio, Inc.$9.3B+287%

Agenus$134.9M-5.0%

Elicio Therapeutics, Inc.$91.7M-32.6%

AIM ImmunoTech$8.0M+18.8%

LIM

Liminatus Pharma, Inc. Class A Common Stock$7.6M-95.9%

By revenue growth

ImmunityBio, Inc.+352%

Baxter International+5.1%

Pfizer+1.4%

By net margin

Pfizer15.65%+6.3pp

Baxter International-9.7%-4.5pp

ImmunityBio, Inc.-606.15%+704pp

Revolution Medicines, Inc.-76,423.32%—

Profile

AIM ImmunoTech is an immuno-pharmaceutical company focused on the research and development of therapeutics for cancers, viral diseases, and immune-deficiency disorders. The company leverages its proprietary double-stranded RNA (dsRNA) technology to enhance the human body's natural antiviral defense system and modify tumor microenvironments. Its core value proposition centers on addressing significant unmet medical needs through its flagship drug candidate, Ampligen.

Competitive position

AIM is a clinical-stage biotechnology firm with a first-in-class dsRNA molecule and orphan drug designations in the US and EU for pancreatic cancer and other rare diseases.

GeographiesUnited States, Argentina, European Union, Japan

Customer segmentsClinical Trial Participants, Specialty Healthcare Providers, Global Pharmaceutical Companies

Business modelResearch and Development, Licensing, Product Commercialization

SuppliersContract Manufacturing Organizations (CMOs), Raw material suppliers for polynucleotides, Human white blood cell suppliers

CustomersClinical trial sites, Early Access Program (EAP) providers, International pharmaceutical distributors

CountryUnited States of America

Listed1995

Employees28.0

CEOThomas K. Equels

SectorHealthcare

IndustryBiotechnology

Websiteaimimmuno.com

FilingsSEC EDGAR

Questions, answered.

What is AIM ImmunoTech's market cap?: AIM ImmunoTech (AIM) has a market capitalization of $8.0M and trades on AMEX.
Who are AIM ImmunoTech's competitors?: AIM ImmunoTech's key competitors include Pfizer, Novartis, Revolution Medicines, and others. These companies compete in similar markets and product categories.
Who does AIM ImmunoTech partner with?: AIM ImmunoTech's notable partners include AstraZeneca, Thermo Fisher Scientific, Merck & Co., and others.
What subsidiaries does AIM ImmunoTech have?: AIM ImmunoTech's subsidiaries include AIM ImmunoTech Europe N.V./S.A..
Where is AIM ImmunoTech headquartered?: AIM ImmunoTech is headquartered in United States of America and employs approximately 28 people. It has been publicly traded since 1995.